Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

PEGS Boston 2020 Resource Page

Explore resources for functional bioassays and protein characterization tools, and learn how we can support your protein engineering research.

Welcome to our resource page for the 16th Annual PEGS Boston virtual event, the Essential Protein Engineering & Cell Therapy Summit. Because we won’t be able to meet you in person, explore this page for information and resources about our portfolio of functional bioassays and protein characterization tools. Learn how we can support your research with our products and technologies.

Visit the PEGS Boston Virtual Event

Immunotherapy Panel Presentation

julia gilden

New Bioluminescent Tools for the Development of TCR-Redirected Therapies

Presented by Julia Gilden, Sr Research Scientist, Integrated Biology, Research & Development, Promega Corporation

This presentation will discuss new bioluminescent tools to expedite the development of T cell-redirecting cancer therapies. First, we will describe two NanoBiT-based assay platforms that can quantitatively measure the potency of CD3 bispecific antibodies or BiTEs to induce T cell-dependent target cell killing and cytokine production. Next, we will describe TCRαβ-null reporter cell lines that can be used to screen transgenic TCRs against specific tumor antigen targets.

View presentation live stream on September 2, 2020 at 1:25 p.m. EDT

tcr-redirected therapies

Scientific Posters

julia gilden Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T-Cell Redirecting Cancer Therapy

Presented by Julia Gilden, Sr. Research Scientist

Download PDF

chris heid

Quantitative Cell-Based Reporter Gene Bioassays to Advance Individual or Combination Cancer Immunotherapy
Presented by Chris Heid, Global Commercialization Manager

Download PDF

brad-swanson-125x125 Rapid and Sensitive Determination of Cytokine Release from Cells without Sample Transfer

Presented by Brad Swanson, Strategic Collaborations Manager

Download PDF

jamison-grailer-125 Cell-Based Reporter Bioassays for Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors

Presented by Jamison Grailer, Sr. Research Scientist

Download PDF

jeff-nelson-125x125 A No-Wash, Rapid FcRn Binding Immunoassay to Guide the Design and Development of Antibody Therapeutics

Presented by Jeff Nelson, Product Manager

Download PDF

steve-edenson-125x125 A Homogenous PBMC ADCC Bioassay Enables Bridging Studies with ADCC Reporter Bioassays in Immunotherapy Monoclonal Antibody Development

Presented by Steve Edenson, Strategic Collaborations Manager

Download PDF

vanessa ott Reproducible, MoA-Reflecting Reporter-Based Bioassays to Enable Drug Development of Biosimilars and Biobetters

Presented by Vanessa Ott, Manager, Biologics

Download PDF

Bioassay Qualification

Bioassays play a critical role in confirming drug mechanisms of action (MOA) during discovery, as well as measuring drug potency and stability. Promega offers a variety of reporter bioassays, cell viability assays and bioassay qualification services.

Bioassay qualification

Biologics Drug Discovery

Biologics are large molecules with complex, heterogeneous structures that are often unstable and sensitive to external conditions. To address these obstacles, Promega provides a broad offering of functional bioassays and protein characterization tools.

biologics drug discovery

Bioassay QC Lot Release

Our bioassays and protein characterization products are manufactured at our headquarters facility, which allows for flexible bulk manufacturing and automated filling and packaging. We are here to assist you will all your manufacturing needs.

bioassay qc lot release

GloMax® Discover Microplate Reader

The GloMax® Discover is an easy-to-use, multimode plate reader for detecting luminescence, fluorescence and absorbance. It functions as a standalone plate reader or can be incorporated into high-throughput automated workflows.

Learn More about GloMax® Discover

Request a Demo

GloMax Discover System Multimode Plate Reader

Would you like more information about our products for biologics drug discovery?

Contact Us